IntelGenx looks to mimic Biovail's success

With its bevy of drug delivery platforms and recent success in Big Pharma partnerships, IntelGenx ($IGXT) is looking to duplicate the success of Biovail, CEO Horst Zerbe said. As Seeking Alpha reports, Zerbe said he's modeling IntelGenx's moves on the company that has since merged with Valeant Pharmaceuticals ($VRX), saying that his firm next needs to develop its own contract research and manufacturing operation, as most manufacturers struggle to produce high-tech platforms like IntelGenx's VersaFilm. Report

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…